Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Esperion Theraptc
(NQ:
ESPR
)
31.30
USD
+2.50 (+8.68%)
Official Closing Price
Updated: 4:32 PM EST, Jan 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Esperion Theraptc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
January 13, 2021
From
GlobeNewswire News Releases
Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
December 21, 2020
From
GlobeNewswire News Releases
First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
December 16, 2020
From
GlobeNewswire News Releases
ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 15, 2020
From
GlobeNewswire News Releases
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Su
November 13, 2020
From
GlobeNewswire News Releases
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
November 12, 2020
From
GlobeNewswire News Releases
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
November 10, 2020
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 06, 2020
From
GlobeNewswire News Releases
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
November 02, 2020
From
GlobeNewswire News Releases
Esperion to Participate in Three Upcoming Virtual Investor Conferences
October 27, 2020
From
GlobeNewswire News Releases
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
October 19, 2020
From
GlobeNewswire News Releases
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
October 07, 2020
- NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 -
From
GlobeNewswire News Releases
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
September 28, 2020
From
GlobeNewswire News Releases
Esperion to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020
From
GlobeNewswire News Releases
Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020
August 26, 2020
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 21, 2020
From
GlobeNewswire News Releases
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
August 10, 2020
From
GlobeNewswire News Releases
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
August 03, 2020
From
GlobeNewswire News Releases
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bemp
July 01, 2020
From
GlobeNewswire News Releases
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
June 22, 2020
From
GlobeNewswire News Releases
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Session
June 14, 2020
From
GlobeNewswire News Releases
Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
June 12, 2020
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
June 08, 2020
From
GlobeNewswire News Releases
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
May 27, 2020
From
GlobeNewswire News Releases
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2020
From
GlobeNewswire News Releases
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
May 07, 2020
From
GlobeNewswire News Releases
Esperion Reports First Quarter 2020 Financial Results and Provides Company Update
May 06, 2020
From
GlobeNewswire News Releases
Esperion to Report First Quarter 2020 Financial Results May 6, 2020
April 30, 2020
From
GlobeNewswire News Releases
Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan
April 20, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.